OTLK Outlook Therapeutics

Watchlist

1.570
+0.090+6.08%

Close Mar 14 16:00 ET

1.570
0.0000.00%

Post 18:42 ET

50.27MMarket Cap-0.63P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Outlook Therapeutics Issues Convertible Note to Avondale
TipRanksMar 14 17:30 ET
Outlook Therapeutics Files to Sell 7.07M Shares of Common Stock for Holders
TipRanksFeb 28 16:40 ET
Outlook Therapeutics Shares Are Trading Higher After the Company Re-submitted Its Biologics License Application for ONS-5010 in Wet AMD to the FDA.
BenzingaFeb 28 08:06 ET
Outlook Therapeutics Re-Submits Its Biologics License Application For ONS-5010 In Wet AMD To The FDA
BenzingaFeb 28 08:06 ET
Express News | Outlook Therapeutics Inc - FDA Decision Expected Within Six Months
ReutersFeb 28 08:05 ET
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
GlobeNewswireFeb 28 08:05 ET

Comments

carlton griffiths

Feb 28 23:46

$Outlook Therapeutics (OTLK.US)$

Trytosaveabit

Feb 28 21:08

Update

$Outlook Therapeutics (OTLK.US)$ Reuters
Just
Outlook Therapeutics® Re-Submits Biologics License Application for Ons-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration! Expected decision within 6 Months

Teddy123

Feb 28 21:07

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

$Outlook Therapeutics (OTLK.US)$
Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint?

Teddy123

Feb 14 21:21

Financial Analysis

$Outlook Therapeutics (OTLK.US)$
The Q1 FY2025 results reveal a complex financial situation requiring careful analysis. While the reported $17.4M net income appears positive, the adjusted net loss of $21.6M reflects significant operational costs and excludes non-cash gains from warrant and convertible note valuations. This 16.7% increase in adjusted net loss compared to the previous year ($10.1M) indicates growing operational expenses as the company approaches commercialization....